The use of other tumor-associated targets, such as HER2 (Shen et al., 2023), PD-L1 (Warmuth et al., 2021; Muik et al., 2022b) or CD40 (Muik et al., 2022a) may require a more extensive safety profiling. The gene discussed is CD40; the disease is neoplasm.